13 episodes

Tim is Stockhead's resident Health and Biotech expert with his weekly column "Dr Boreham's Crucible". Tim was the author of the Criterion column in The Australian newspaper for well over 10 years and has more than three decades' experience of business reporting across three major publications.

In his weekly "The Health Kick Podcast" Tim will interview Australia's leading Health and Biotech industry leaders, bringing his own unique insight and perspective into the world of health and drug discovery.

The Health Kick Podcast with Tim Boreham Stockhead

    • Health & Fitness

Tim is Stockhead's resident Health and Biotech expert with his weekly column "Dr Boreham's Crucible". Tim was the author of the Criterion column in The Australian newspaper for well over 10 years and has more than three decades' experience of business reporting across three major publications.

In his weekly "The Health Kick Podcast" Tim will interview Australia's leading Health and Biotech industry leaders, bringing his own unique insight and perspective into the world of health and drug discovery.

    Commercialising orphan drugs, the need for better biotech regulation the ASX's lifestyle play problems

    Commercialising orphan drugs, the need for better biotech regulation the ASX's lifestyle play problems

    Tim chats with Race Oncology (ASX:RCE) CEO Peter Molloy and executive director and CSO Daniel Tillett.

    • 26 min
    The science behind 2019's hottest IPO and the company's next steps

    The science behind 2019's hottest IPO and the company's next steps

    Tim chats with Osteopore (ASX:OSX) executive director Geoff Pocock

    • 21 min
    Investing in repurposed drugs, combatting intracranial pressure and why Invex caught NASA's eye

    Investing in repurposed drugs, combatting intracranial pressure and why Invex caught NASA's eye

    Tim speaks with Invex founder and CEO Alex Sinclair, as well as the company's chairman Dr Jason Loveridge.

    • 19 min
    What's holding back better breast cancer detection? And how is Volpara's tech changing the game?

    What's holding back better breast cancer detection? And how is Volpara's tech changing the game?

    Tim chats with executive director and CEO of Volpara Health Technologies Ralph Highnam.

    • 21 min
    Developing drugs, fighting fibrosis and squeezing squishometers

    Developing drugs, fighting fibrosis and squeezing squishometers

    Tim chats with CEO and MD Dimerix Nina Webster, and CEO of Pharmaxis Gary Phillips.

    • 23 min
    How Aussie health stocks are performing internationally and Prescient's cancer-blocking innovation

    How Aussie health stocks are performing internationally and Prescient's cancer-blocking innovation

    Tim chats with Steven Yatomi-Clarke, CEO and managing director of Prescient Therapeutics (ASX:PTX).

    • 18 min

Customer Reviews

Cruziac Killer ,

Very informative

Great listening

nick Suners ,

Useful for investors

I quite liked this podcast, found it very useful

cassiegeselle ,

Well hosted

Good podcast

Top Podcasts In Health & Fitness

Listeners Also Subscribed To